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Subcellular localization of CrmA: identification of a novel leucine-rich
nuclear export signal conserved in anti-apoptotic serpins
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The cowpox virus-encoded anti-apoptotic protein cytokine
response modifier A (CrmA) is a member of the serpin family
that specifically inhibits the cellular proteins caspase 1, caspase
8 and granzyme B. In this study, we have used Flag- and yellow
fluorescent protein (YFP)-tagged versions of CrmA to investigate
the mechanisms that regulate its subcellular localization. We show
that CrmA can actively enter and exit the nucleus and we dem-
onstrate the role of the nuclear export receptor CRM1 in this
shuttling process. CrmA contains a novel leucine-rich nuclear
export signal (NES) that is functionally conserved in the anti-
apoptotic cellular serpin PI-9. Besides this leucine-rich export
signal, additional sequences mapping to a 103-amino-acid region
flanking the NES contribute to the CRM1-dependent nuclear
export of CrmA. Although YFP-tagged CrmA is primarily located
in the cytoplasm, shifting its localization to be predominantly
nuclear by fusion of a heterologous nuclear localization signal
did not impair its ability to prevent Fas-induced apoptosis. We
propose that nucleocytoplasmic shuttling would allow CrmA to
efficiently target cellular pro-apoptotic proteins not only in the
cytoplasm, but also in the nucleus, and thus to carry out its anti-
apoptotic function in both compartments.
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INTRODUCTION
The regulated self-destruction of a cell by apoptosis constitutes
a complex process that involves the co-ordinated activity of
proteins localized to different subcellular compartments, such
as the cell membrane, cytoplasm, mitochondria and nucleus.
The apoptotic pathway triggered by the interaction between the
death receptor Fas (CD95/APO-1) and its ligand on the cell
membrane clearly illustrates this complexity (reviewed in [1]).
Ligand binding leads to oligomerization of Fas and recruitment
of cytoplasmic pro-caspase 8 to the intracellular domain of the
receptor. Recruitment to the receptor, mediated by the adaptor
protein FADD (Fas-associated death domain), results in the self-
processing and activation of caspase 8 which, in turn, initiates
a cascade of caspase-mediated proteolytic events that eventually
leads to DNA fragmentation and degradation of nuclear proteins.
Because activation of the caspase cascade in the cytoplasm
ultimately leads to a series of nuclear changes that constitute
classical hallmarks of apoptosis, the relay of the apoptotic signal
to the nucleus is thought to represent an important step in the
apoptotic process [2].
Communication between the nucleus and cytoplasm takes place
through the nuclear pore complexes, gated channels that penetrate
the double membrane of the nuclear envelope [3]. The diameter
of these channels allows free diffusion of small molecules,
but translocation of many proteins across the nuclear envelope
involves active transport mechanisms mediated by specific import
or export receptors [4]. Selective transport in and out of the
nucleus depends on the presence of nuclear localization signals
(NLSs) or nuclear export signals (NESs) in the cargo protein, that
are recognized by the import and export receptors respectively
[5,6]. How the nucleocytoplasmic transport machinery is involved
in conveying the apoptotic signal to the nucleus remains to be
clearly established. Elucidating the mechanisms and identifying
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the signals that regulate the nucleocytoplasmic localization of the
proteins that are involved in the execution or regulation of
apoptosis may contribute to our understanding of this process.
Several viruses have evolved proteins that interfere with the cel-
lular apoptotic machinery as a mechanism to counteract the host
immune response to infection. One of the best-characterized
viral anti-apoptotic proteins is the cowpox virus-encoded CrmA
(cytokine response modifier A), a 38 kDa protein member of the
serine protease inhibitor (serpin) superfamily [7]. CrmA plays a
critical role in viral pathogenesis by inactivating three cellular
proteases: caspase 1, caspase 8 and granzyme B [7–11]. By
targeting caspase 8 and granzyme B, CrmA blocks cytotoxic T
lymphocyte-induced suicide of infected cells mediated by the Fas
or the perforin/granzyme apoptotic pathways [9–11]. On the other
hand, inhibition of caspase 1 prevents the proteolytic activation
of pro-interleukin-1β [7,8], compromising the host inflammatory
response. Besides its physiological role, CrmA is widely used
as a tool to determine the role of particular pathways in the
cellular response to different pro-apoptotic stimuli due to its
target specificity [12–14].
The subcellular localization of the three cellular proteases
targeted by CrmA has been addressed in several reports [15–
21]. They have been shown to enter the nucleus during apoptosis
[15–17,21], and a classical NLS has been identified in the pro-
domain of caspase 1 [18]. CrmA has been shown previously to
localize to either the cytoplasm [7] or both to the nucleus and
cytoplasm [22], but the transport mechanisms and signals that
regulate its subcellular localization have not been defined. The
current view is that its small size allows CrmA to freely diffuse
through the nuclear pores into the nucleus [22]. We show here that,
besides passive diffusion, active cellular mechanisms of nucleo-
cytoplasmic transport, including CRM1-dependent nuclear ex-
port, determine the subcellular localization of CrmA. We have
identified and characterized in detail a novel leucine-rich NES in
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CrmA that is functionally conserved in the cellular anti-apoptotic
serpin PI-9. Interestingly, CRM1-dependent nuclear export of
CrmA is mediated not only by its leucine-rich export signal, but
also by additional sequences that we mapped to a 103-amino-acid
segment flanking the NES. The ability of CrmA to shuttle between
the two cellular compartments suggests that it may function as an
anti-apoptotic protein not only in the cytoplasm, but also in the
nucleus. In support of this possibility, we show that the ability of
yellow fluorescent protein (YFP)-CrmA, a primarily cytoplasmic
protein, to prevent Fas-induced apoptosis is fully preserved when
its localization is artificially shifted to be predominantly nuclear
by the fusion of a heterologous NLS.
MATERIALS AND METHODS
Cell culture, transfection and leptomycin B (LMB) treatment
Human tumour-derived cell lines MCF-7 (breast carcinoma),
HeLa (cervical carcinoma), A431 (vulval carcinoma), SW1573
(lung carcinoma) and HepG2 (hepatic carcinoma) were grown in
RPMI or Dulbecco’s modified Eagle’s medium (BioWhittaker),
supplemented with 10% (v/v) fetal calf serum, 100 units/ml
penicillin and 100 µg/ml streptomycin (Gibco BRL). Cells were
seeded on to sterile glass coverslips in 6- or 12-well trays, and
transfected with 0.5–2 µg of plasmid DNA using the FuGene6
transfection reagent (Roche Molecular Biochemicals), following
the manufacturer’s protocol. LMB (generously provided by
Dr Minoru Yoshida, University of Tokyo, Tokyo, Japan) was
added to the culture medium to a final concentration of 6 ng/ml
and the cells were incubated at 37 ◦C for the indicated period
of time.
Cloning procedures and plasmid construction
The mammalian expression vectors pEF-FlagpGKpuro-CrmAwt
and pEF-FlagpGKpuro-CrmAmt, encoding Flag-tagged wild-
type CrmA or an inactive point mutant (Thr291 → Arg) variant
respectively [14], were generously provided by Dr David L.
Vaux (The Walter and Eliza Hall Institute of Medical Research,
Melbourne, Australia). To generate the plasmid encoding Flag-
CrmA + NLS, the NLS of the simian virus 40 (SV40) large T
antigen (PKKKRKV) [23] was cloned at the C-terminal end of
wild-type CrmA using PCR with primers JAR34 and JAR61
(Table 1). The PCR product, digested with NdeI and XbaI
restriction enzymes (Roche Molecular Biochemicals), was used
to replace an NdeI/XbaI-excised fragment at the 3′-end of CrmA
cDNA. To create the YFP-tagged versions of CrmA, CrmAT291R
and CrmA + NLS, the corresponding cDNAs were amplified by
PCR using primer set JAR51/JAR56 (CrmA wt and T291R)
or JAR51/JAR83 (CrmA + NLS) and cloned as HindIII/KpnI
fragments into the pEYFP-C1 expression plasmid (Clontech, Palo
Alto, CA, U.S.A.). PCR was also used to generate the deletion
mutants of CrmA fused to YFP. The primer sets used to amplify
each CrmA fragment were JAR51/JAR52 (residues 1–149),
JAR53/JAR56 (100–341), JAR55/JAR56 (200–341), JAR53/
JAR54 (100–270), JAR100/JAR102 (150–200), JAR55/JAR54
(200–270) and JAR101/JAR72 (263–303).
The DNA segments encoding the NES-like sequences of CrmA
and a short flanking region were amplified by PCR using CrmA
cDNA as template and cloned as BamHI/AgeI fragments into the
previously described Rev(1.4)-GFP plasmid [24] (where GFP is
green fluorescent protein). This plasmid, as well as the positive
control for the export assay containing the wild-type Rev NES,
were kindly provided by Dr Beric R. Henderson (The Westmead
Institute for Cancer Research, Sydney, Australia). The primer sets
Table 1 Sequences of the oligonucleotides used in cloning, plasmid
construction and site-directed mutagenesis
Oligonucleotide Sequence 5′ → 3′
JAR10 CGG GCC CGG GAT CCA GGC TCG TAT AAT CTG
JAR11 GTG GCG ACC GGT GGG AAC ACC TCT GTC AG
JAR24 GTG GCG ACC GGT GGG AAC ACC TCT GTC GCT CCC AA
JAR25 GTG GCG ACC GGT GGG AAC ACC TCT GTC AGT CCC GCC TTT AC
JAR32 GTA AAG GCG GGA GCG ACA GAG GTG TTC GGT TCA AC
JAR33 CTC TGT CGC TCC CGC CTT TAC TAG CGC ATC CAC CAG
JAR34 AGG CAT TTA ATC ACG CAT CTG
JAR35 ACG TGG GAG ACC TGA TAC TCT C
JAR51 TTA GTA CAA GCT TCG ATG GAT ATC TTC AGG G
JAR52 AAT GGA GGT ACC TCA ATA ATC ACT GGT AAA TTC C
JAR53 TTA GTA CAA GCT TCG AAG TGT GTT GAT ATC TTC
JAR54 AAT GGA GGT ACC TCA ACA CAT ATT GCT ATA ATC
JAR55 TTA GTA CAA GCT TCG CCA GAC AAT ATT GAT GG
JAR56 AAT GGA GGT ACC TTA ATT AGT TGT TGG AG
JAR61 GAC TAG TCT AGA TTA GAC TTT GCG CTT CTT CTT
AGG ATT AGT TGT TGG AGA GCA ATA TC
JAR65 CGG GCC CGG GAT CCA TGT GAC TCT ATG GAT G
JAR66 GTG GCG ACC GGT GGA TAC GAG CCT GTT AC
JAR72 AAT GGA GGT ACC TTA GTC TGC CAC CAG CGC AC
JAR75 CGG GCC CGG GAT CCA GGA ACC TAT GAT CTG
JAR76 GTG GCG ACC GGT GGG AAG ACC TTA GTG ATG
JAR77 CGG GCC CGG GAT CCA GAG GAT TAT GAC ATG
JAR78 GTG GCG ACC GGT GGG AAG GCA TCA ACA ATT
JAR79 CGG GCC CGG GAT CCA AAG ATG ATT GAT CCC
JAR80 GTG GCG ACC GGT GGG AAG ATA TGT TTC AG
JAR83 AAT GGA GGT ACC TTA GAC TTT GCG CTT CTT C
JAR100 TTA GTA CAA GCT TCG CCC TTT TAC GTA TCT CC
JAR102 AAT GGA GGT ACC TCA AAG AAT TAC CAC CAT AC
used were JAR10/JAR11 [CrmA-(242–259)] and JAR65/JAR66
[CrmA-(223–244)]. Similarly, the DNA segments encoding the
amino acid sequences of α1-antitrypsin, PI-9, and Maspin similar
to CrmA NES were amplified by PCR using genomic or
cDNA from Jurkat cells as template, and cloned as BamHI/AgeI
fragments into Rev(1.4)-GFP. The primer sets used in this case
were JAR75/JAR76 (α1-antitrypsin), JAR77/JAR78 (PI-9) and
JAR79/JAR80 (Maspin). The single amino acid substitutions
of CrmA NES in the export assay construct were generated
using mutagenic PCR primers JAR24 (Leu255 → Ala) and JAR25
(Leu253 → Ala) in combination with JAR10. In all cases, the high
fidelity DNA polymerase Pfu (Stratagene, La Jolla, CA, U.S.A.)
was used in the PCR reactions, and the sequence of the inserts was
verified by DNA sequencing.
Site-directed mutagenesis of CrmA NES
A two-step PCR-based site-directed mutagenesis approach was
used to generate the NES-defective CrmANES, introducing two
point mutations (Leu253 → Ala and Leu255 → Ala) in the NES
of CrmA. Two overlapping PCR fragments were amplified
with primer combinations JAR34/JAR33 and JAR32/JAR35.
Following gel-purification, the PCR products were mixed, ann-
ealed, and used as template for a second round of amplification
with primers JAR34 and JAR35. The product of this second
reaction was digested with NdeI and XbaI and used to replace the
NdeI/XbaI-excised 3′-end of CrmA. After confirming the presence
of the mutation by DNA sequencing, this plasmid was used as
template in PCR reactions to generate YFP-CrmANESm (primer
set JAR51/JAR56), and the different YFP-fusion fragments of
CrmA containing the NES mutation: 100–341NESm (primer set
JAR53/JAR56), 200–341NESm (primer set JAR55/JAR56), 200–
303NESm (primer set JAR 55/JAR72), and 200–270NESm (primer set
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JAR55/JAR54). In all cases, the PCR products were inserted as
HindIII/KpnI fragments into pEYFP-C1.
Immunocytochemistry, fluorescence microscopy analysis
and quantification of subcellular distribution
Cells transfected with plasmids encoding YFP-tagged proteins
were fixed with 3.7% formaldehyde in PBS for 30 min at room
temperature, stained with the chromosome dye Hoechst 33285
(Sigma) for 30 min to counterstain the nuclei, and mounted
on to microscope slides using Vectashield (Vector). Immuno-
cytochemical detection of Flag-tagged CrmA was performed
with the anti-Flag M2 monoclonal antibody (Stratagene), and a
fluorescein isothiocyanate-conjugated goat anti-mouse secondary
antibody (Santa Cruz), using a previously described immuno-
staining method [25]. Fluorescence microscopy analysis was
carried out using an inverted Leica DMIRB/E fluorescence
microscope (Leica Heidelberg, Heidelberg, Germany). Images
were collected using the Q500MC Quantimet software V01.01
(Leica Cambridge, Cambridge, U.K.). To quantitatively determine
their subcellular distribution, the localization of the ectopically ex-
pressed proteins was assessed in at least 200 transfected cells per
sample. The degree of LMB-induced nuclear accumulation of pro-
teins (LMB effect) was calculated as described previously [25].
In vivo Rev(1.4)-GFP nuclear export assay
The NES-like motifs in CrmA and other serpins were tested for
export activity using the Rev(1.4)-GFP in vivo nuclear export
assay [24]. Duplicate samples of MCF-7 cells were transfected
with pRev(1.4)-GFP (negative control) and its derivative plasmids
containing each of the candidate export sequences or the wild-type
Rev NES (as positive control). At 24 h post-transfection, cells
were treated for 3 h with either 10 µg/ml cycloheximide (CHX)
plus 5 µg/ml actinomycin D or with CHX alone. CHX treatment
ensures that cytoplasmic GFP arises from nuclear export and not
from new protein synthesis, whereas actinomycin D prevents, by
an undefined mechanism, the nuclear import of Rev and thus
allows detection of weaker NESs. The subcellular localization
of the GFP-fusion proteins was determined in at least 200 cells
per sample and the activity of the functional NESs was rated
according to the published scoring system [24].
The CRM1-dependence of the functional NESs identified in the
nuclear export assay was further confirmed by LMB treatment of
the transfected cells (6 ng/ml for 3 h).
Sequence alignment analysis
The amino acid sequence comparison between CrmA and cellular
serpins was carried out using the BLASTP 2.2.3 program available
at the National Center for Biotechnology Information website
(www.ncbi.nlm.nih.gov).
Induction and evaluation of Fas-dependent apoptosis
Duplicate samples of HeLa cells were transfected with expression
plasmids encoding three YFP-tagged variants of CrmA: the
wild-type protein, CrmA + NLS and, as control, the previously
described loss-of-function mutant T291R [14]. At 24 h post-
transfection, cells were treated with 100 ng/ml anti-Fas activating
human monoclonal antibody CH11 (Upstate Biotechnology) plus
2 µg/ml CHX. After 20 h of incubation under control conditions
or in the presence of anti-Fas/CHX, cells were examined using an
inverted Leica DMIRB/E fluorescence microscope under UV and
visible light. Viable cells were scored as those that remained
attached to the plate and did not show morphological signs of
apoptosis. The percentage of viability of transfected cells was
determined by examining at least five independent microscopy
fields and counting more than 600 YFP-positive cells. As a
marker for apoptotic cell death, the cleavage of poly(ADP-ribose)
polymerase (PARP) was determined, as previously described [26],
in protein extracts generated from the detached and attached
cell sub-populations of samples transfected with YFP-CrmA and
YFP-CrmA + NLS. We also used an anti-GFP antibody (Sigma)
to determine the expression of YFP-CrmA and YFP-CrmA +
NLS in these cell sub-populations, and anti-actin antibody
(Sigma) to control for equal protein loading.
RESULTS
The nucleocytoplasmic localization of CrmA is regulated
by cellular mechanisms of active transport, including
CRM1-dependent nuclear export
To investigate its subcellular localization, we transfected HeLa
human cervical carcinoma cells with expression vectors encoding
CrmA tagged with either a Flag epitope (Flag-CrmA) or YFP
(YFP-CrmA). Fluorescence microscopy analysis (Figure 1A) of
CrmA-expressing cells revealed a complex pattern of nucleo-
cytoplasmic distribution, with CrmA being present only in
the cytoplasm of some cells, but localizing to either the nucleus
or both the nucleus and cytoplasm of other cells. The subcellular
distribution of CrmA was influenced by the size of the tag used:
the 65 kDa non-diffusing YFP-CrmA fusion protein was more
often excluded from the nucleus than the smaller Flag-CrmA. We
extended the analysis of YFP-CrmA localization to a broader
panel of human cells derived from different types of tumour
(Table 2). In every cell line tested, approx. 20–30% of the
transfected cells showed at least partial nuclear accumulation of
YFP-CrmA. This indicates that nuclear import of CrmA occurs,
at least in part, by an active mechanism.
These observations, and a recent report that the localization
of the cellular serpin PI-9 is regulated by the export receptor
CRM1 [22], prompted us to investigate the possibility that
CrmA undergoes CRM1-dependent nuclear export. Treatment of
the cells with the specific CRM1 inhibitor LMB [27] resulted
in a consistent relocation of CrmA to the nucleus of MCF-7
and HeLa cells (Figure 1B), indicating a role for CRM1 as
a mediator of CrmA nuclear export. The limited LMB effect
observed could be due either to a slow rate of nuclear import or
to the selective retention of CrmA in the cytoplasm caused by
interaction with other proteins. Fusion of the NLS of the SV40
large T antigen [23] to the C-terminus of CrmA readily induced
the nuclear accumulation of CrmA (see below and Figure 6A),
indicating that a slow rate of nuclear import is largely responsible
for the limited nuclear accumulation of CrmA upon LMB
treatment, whereas cytoplasmic retention plays only a minor
role. Altogether, these findings indicate that, in addition to
the previously described diffusion through the nuclear pore, a
slow rate of active nuclear import and CRM1-dependent nuclear
export are major determinants of the subcellular localization of
CrmA.
CrmA contains a functional leucine-rich NES
To map the regions involved in regulating CrmA nucleocytoplas-
mic transport, we generated a series of deletion mutants of CrmA
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Figure 1 Subcellular localization and response to LMB of epitope-tagged
CrmA
(A) Representative examples of transfected HeLa cells expressing Flag-CrmA (left panels) or
YFP-CrmA (right panels). In some transfected cells, the localization of CrmA was predominantly
nuclear (N), whereas it was both nuclear and cytoplasmic (NC), or predominantly cytoplasmic
(C) in other cells. The proportion of cells showing each type of subcellular localization, indicated
in each panel, was determined by counting more than 500 cells. Cells were counterstained with
Hoechst to visualize the nuclei. (B) Incubation of HeLa or MCF-7 cells expressing Flag- or YFP-
tagged CrmA in the presence of 6 ng/ml of the specific inhibitor LMB (+ 8 h LMB) increases
the proportion of cells showing either nuclear (N) or nuclear and cytoplasmic (NC) CrmA with
respect to untreated cells (control). Graphs show the results (mean +− S.D.) of at least three
independent experiments in which the subcellular localization of CrmA was scored in more than
200 individual cells per experiment. The LMB effect was calculated as previously described
[25].
Table 2 Nucleocytoplasmic distribution of YFP-tagged CrmA in human
tumour cell lines
Cells were transfected with a plasmid encoding YFP-CrmA and the proportion of cells expressing
the ectopic protein in the nucleus (N), cytoplasm (C) or both (NC) was determined by counting
the indicated number of cells (n).
Cell line Origin n N (%) NC (%) C (%)
MCF-7 Breast carcinoma 944 3.2 17.5 79.3
SW1573 Lung carcinoma 633 4.2 22 73.8
A431 Vulval carcinoma 540 3.5 25 71.5
HepG2 Hepatic carcinoma 590 3.4 27.5 69.1
HeLa Cervical carcinoma 1856 5.0 26.6 68.4
Figure 2 Deletion analysis to map the CrmA region responsible for nuclear
export
A series of YFP-tagged truncated fragments of CrmA, schematically represented on the left,
were expressed in MCF-7 cells. The subcellular distribution of each fragment in the absence
(untreated) or presence (3 h LMB) of LMB is shown in the right. Only the percentage of
cells expressing the YFP-fusion proteins predominantly in the nucleus (%N) or the cytoplasm
(%C) is indicated. The remaining cells (results not shown) expressed similar levels in both
compartments. Results are the mean of two independent experiments with less than 10 %
variation. More than 200 cells per sample were counted in each experiment. The clear LMB
effect on CrmA-(200–270) suggests the presence of sequences mediating CRM1-dependent
nuclear export in this fragment.
fused to YFP. These constructs were transfected into MCF-7 cells
and the subcellular distribution, as well as the response to LMB
treatment of each region, was determined. As shown in Figure 2,
the localization of CrmA fragments encompassing amino acids
1–149 and 150–200 did not change following incubation with
LMB for 3 h. In contrast, LMB treatment induced a dramatic
relocation of the other four CrmA fragments to the nucleus,
which was already evident at 30 min after addition of the drug
(results not shown). The results of this analysis clearly indicated
the presence of sequences mediating CRM1-dependent nuclear
export in the segment encompassing CrmA amino acids 200–
270. In addition, the intense and rapid nuclear accumulation of
the deletion mutant YFP-CrmA-(100–341) upon LMB treatment
provides further evidence that CrmA is actively imported into the
nucleus and, importantly, shows that sequences in the N-terminal
region of CrmA may negatively regulate this process.
Visual examination of the amino acid sequence of CrmA seg-
ment 200–270 revealed the presence of three motifs that resemble
the NES of HIV Rev protein (Figure 3A). These motifs consist of
a cluster of large hydrophobic amino acids with a characteristic
spacing. To determine if these NES-like motifs function as CRM1-
dependent export signals, we used a recently developed in vivo
nuclear export assay [24]. In this assay, the ability of a potential
NES to complement the inactivated NES of the Rev(1.4) mutant
protein is assessed. The export-deficient fluorescent protein
Rev(1.4)-GFP is trapped in the nucleus, and active NESs are
identified by their ability to induce its relocation to the cytoplasm
when inserted between the Rev(1.4) and the GFP moieties. The
extent of this relocation reflects the strength of the NES tested
and thus the activity of different NESs can be compared and
classified according to the proportion of cells with cytoplasmic
GFP.
Two short fragments of CrmA encompassing the NES-like
motifs and a few flanking residues were cloned into Rev(1.4)-GFP
and transfected into MCF-7 cells, along with negative [Rev(1.4)-
GFP with no inserted NES sequence] and positive [with the wild-
type Rev NES re-inserted between Rev(1.4) and GFP] controls.
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Figure 3 Identification and characterization of a functional leucine-rich
NES in CrmA
(A) Sequence comparison between the NES of HIV Rev protein and three NES-like motifs in
CrmA segment 200–270. The large hydrophobic residues that conform to the consensus NES
spacing are boxed. (B) In vivo nuclear export assay in MCF-7 cells demonstrating that the
CrmA fragment 242–259, containing the NES-like motif III, constitutes an active transferable
NES, which induced the cytoplasmic accumulation of the nuclear Rev(1.4)-GFP protein
(negative control). In contrast, CrmA fragment 223–244 showed no export activity in this
assay. The subcellular distribution of each protein is indicated in the insets: N, nuclear;
NC, nuclear and cytoplasmic; C, cytoplasmic. Results are the mean of two independent
experiments with less than 10 % variation. More than 200 cells per sample were counted
in each experiment. According to the scoring system used in this assay [24], the activity of CrmA
NES was classified as 9+, the same as that of Rev NES (positive control). Act.D, actinomycin
D. (C) LMB treatment (6 ng/ml for 3 h) or mutagenesis of leucine residues Leu253 or Leu255
to alanine (Leu253Ala and Leu 255Ala respectively) abrogates CrmA NES-mediated nuclear
export.
The overlapping NES-like motifs I and II were tested using a
single fragment (223–244). As shown in Figure 3(B), only the
CrmA fragment 242–259, which includes NES-like motif III, was
able to induce the relocation of Rev(1.4)-GFP to the cytoplasm,
indicating that this motif constitutes a functional, transferable
NES. Under the conditions of this assay, the CrmA NES was
as active as the Rev NES, resulting in >80% cytoplasmic
localization of GFP, even in the presence of active Rev-mediated
import (untreated samples in Figure 3B). The export activity of
CrmA NES was therefore classified as 9+, the highest score in
the NES scoring system used with this export assay [24].
Incubation with LMB or with mutants containing leucine-
to-alanine substitutions of two of the residues that conform to
the consensus NES sequence (Leu253 and Leu255) (Figure 3C)
efficiently abrogated CrmA NES-induced relocation of Rev(1.4)-
GFP to the cytoplasm. These results therefore confirmed that the
CrmA NES mediates nuclear export via the CRM1-dependent
pathway, and identified critical residues for its activity.
The NES is functionally conserved in the cellular anti-apoptotic
serpin PI-9
An amino acid sequence comparison between CrmA and a number
of cellular serpins revealed that the four leucine residues that
conform to the consensus NES motif are commonly conserved or
changed to another hydrophobic residue such as methionine
or isoleucine (Figure 4A). Thus the functionality of the signal
might a priori be preserved, as such residues are often found
in functional export signals, such as the NESs of PKI (protein
kinase inhibitor) [28] or Ran-BP1 [29]. On the other hand, the
neighbouring residues may also affect the activity of an NES [24]
and therefore the functional status of this sequence in the different
serpins cannot be directly inferred from sequence similarity.
Using the nuclear export assay, we tested the region of identity
with CrmA NES corresponding to the cellular serpins PI-9, α1-
antitrypsin and Maspin. Of the three sequences tested, which
show a variable degree of similarity to CrmA NES, only the PI-9
motif was found to be a functional NES (Figure 4B). The export
activity of PI-9 NES was classified as 2+, considerably weaker
than CrmA NES in this assay.
Additional sequences flanking the NES contribute to CrmA
nuclear export
To analyse the activity of the NES in the context of the full-length
protein, we used site-directed mutagenesis to generate a NES-
defective CrmA variant (CrmANESm) containing two leucine-to-
alanine point mutations that abrogate the activity of the NES in the
nuclear export assay (Leu253 → Ala and Leu255 → Ala, Figure 5A).
Although the localization of Flag-CrmANESm in HeLa cells was
less cytoplasmic than that of the wild-type protein, the mutational
inactivation of the NES did not fully account for the LMB response
(Figure 5B, upper panel). Similar results were observed for
YFP-CrmANESm (results not shown). Since the CrmA N-terminal
region negatively regulates its nuclear import (see Figure 2),
we introduced the NES-inactivating substitutions into the CrmA
deletion mutant lacking the first 100 amino acids. Inactivation of
the NES had a more dramatic effect in the context of CrmA-
(100–341) (Figure 5B, lower panel). The proportion of cells
showing nuclear localization of this protein increased markedly
and its cytoplasmic localization was almost completely abrogated.
However, as observed for its full-length counterpart, inactivation
of the NES did not fully account for the LMB response, and the
nuclear relocation of CrmA-(100–341)NESm was further enhanced
by treatment with LMB. Surprisingly, CrmANESm was more
cytoplasmic than the wild-type protein in MCF-7 cells (results not
shown), and its nuclear accumulation in reponse to LMB cells was
decreased, suggesting that the Leu253 → Ala and Leu255 → Ala
mutations may interfere with the nuclear import of CrmA in
MCF-7 cells.
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A
B
Figure 4 Functional conservation of the NES in the anti-apoptotic cellular serpin PI-9
(A) Amino acid sequence comparison between CrmA NES and similar regions in other serpins. The large hydrophobic amino acids that conform to the consensus NES are boxed. MENT, myeloid
and erythroid nuclear termination stage-specific protein. (B) In vivo nuclear export assay showing that PI-9 fragment 276–293, similar to CrmA 242–259, is a functional NES, able to relocate
Rev(1.4)-GFP to the cytoplasm of MCF-7 cells when Rev-mediated nuclear import is blocked by actinomycin D (Act. D) incubation. On the basis of the subcellular distribution of GFP (insets), the
activity of PI-9 NES was classified as 2+. The regions of identity with CrmA NES in α1-antitrypsin and Maspin were inactive as export signals when tested in this assay.
These results therefore clearly indicate that the NES is only
partially responsible for CrmA nuclear export in HeLa cells.
According to the deletion analysis shown in Figure 2, other
sequence motifs that might contribute to CRM1-dependent
nuclear export of CrmA should be located within the CrmA region
200–341. To more precisely map these elements, we first tested
two NES-like sequences located in this region (S195MVVI
LPDNIDGLESIEQNL and 316HPFIYVIRHVDGKILFVGRYC;
one-letter amino acid symbols, with bold letters highlighting
residues of interest). Both sequences were negative in the nuclear
export assay (results not shown). Next, we introduced the
NES-inactivating mutations into YFP-tagged CrmA fragments
spanning the 200–341 segment (Figure 5C). LMB treatment
increased the nuclear localization of YFP-CrmA-(200–341)NESm
and YFP–CrmA-(200–303)NESm. However, further N- or C-
terminal deletions abrogated the response to LMB. Combined,
the results of this analysis enabled us to map the sequences
responsible for NES-independent nuclear export of CrmA to
an amino acid segment flanking the NES, comprising residues
200–303. Importantly, this region does not appear to contain other
functional leucine-rich export signals.
Enhanced nuclear localization does not alter the ability of CrmA
to prevent Fas-induced apoptosis
The ability of CrmA to undergo active nucleocytoplasmic
transport suggests that it might carry out its anti-apoptotic function
not only in the cytoplasm, but also in the nucleus. To optimally
address this possibility, the anti-apoptotic activity of CrmA when
exclusively located to the nucleus should be tested. This was
hampered by the slow rate of nuclear import of CrmA and the fact
that inactivating the NES does not fully prevent its nuclear export.
One would expect, however, that enhancing the accumulation
of CrmA in the nucleus would decrease its activity, if nuclear
CrmA were unable to prevent apoptosis. Therefore we fused
the strong NLS of the SV40 large T antigen to the C-terminal
end of CrmA to generate a chimaeric protein (CrmA + NLS),
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Figure 5 Additional CrmA sequences flanking the NES contribute to CrmA
nuclear export
(A) Schematic representation of CrmA showing the location of the NES and the amino-acid
substitutions (Leu253 → Ala and Leu255 → Ala) introduced by site-directed mutagenesis to
generate NES-defective CrmANESm. (B) Effect of mutational inactivation of the NES in the context
of full-length Flag-CrmA (upper panel) and YFP-CrmA-(100–341) (lower panel). The NES
mutation had a more dramatic effect on the localization of the N-terminally truncated protein.
In both cases, however, the nuclear relocation of CrmANESm was further enhanced by LMB
treatment, suggesting the presence of additional export-mediating sequences. Bars represent
the proportion of HeLa cells showing predominantly nuclear (N) or cytoplasmic (C) CrmA in the
absence or presence of LMB (6 ng/ml for 6 h), and are the mean +− S.D. of three independent
experiments. More than 200 transfected cells per sample were counted in each experiment.
(C) Four YFP-tagged C-terminal fragments of CrmA lacking an active NES (depicted on the left)
were transiently expressed in HeLa cells. The ability of each fragment to undergo LMB-induced
nuclear relocation (LMB response) is indicated on the right.
whose nuclear accumulation is dramatically enhanced with
respect to that of CrmA (Figure 6A). We next compared the
ability of YFP-CrmA and YFP-CrmA + NLS to prevent Fas-
induced apoptosis of HeLa cells. The use of YFP-tagged proteins
enabled us to correlate the viability of transfected cells with
the localization of CrmA on a single-cell basis. As a negative
control, cells were transfected with YFP-CrmAT291R, a loss-of-
function mutant of CrmA described previously [14]. At 24 h post
transfection, cells were treated with anti-Fas agonistic antibody
CH11 plus CHX for 20 h and the viability of transfected cells was
assessed by fluorescence microscopy. After treatment, virtually all
non-transfected cells (results not shown) and cells expressing
YFP-CrmAT291R (Figure 6B) had detached from the bottom
of the tissue culture tray and exhibited nuclear shrinkage and
membrane blebbing characteristic of apoptotic cell death. In
contrast, cells expressing wild-type YFP-CrmA (predominantly
cytoplasmic) or YFP-CrmA + NLS (predominantly nuclear) re-
mained attached and did not show any morphological evidence
of apoptosis. The cleavage of PARP, determined by Western
blot analysis (Figure 6C), confirmed that the detached, non-
transfected cells had undergone apoptosis. These results therefore
indicate that a dramatic nuclear relocation does not impair
A
Figure 6 Enhanced nuclear localization does not alter the ability of CrmA
to prevent Fas-induced apoptosis
(A) C-terminal fusion of the SV40 large T antigen NLS induces accumulation of CrmA into
the nucleus. Photographs show representative examples of HeLa cells expressing YFP-CrmA
(predominantly cytoplasmic) or YFP-CrmA + NLS (predominantly nuclear). Middle panels show
the cell nucleus stained with Hoechst. Graphs show the subcellular distribution of each protein.
(B) Graphs show the proportion of transfected HeLa cells showing no morphological evidence of
apoptosis in untreated samples (–) or after a 20 h incubation with 100 ng/ml anti-Fas agonistic
antibody CH11 plus 2 µg/ml CHX (+). Bars represent the mean +− S.D. of five independent
microscopic fields. The viability was assessed in a single-cell basis and at least 100 YFP-positive
cells per field were counted. (C) Western blot analysis of protein samples from the cells that
had detached (Det) or that remained attached (Att) to the bottom of the six-well tray after 20 h
incubation with anti-Fas agonistic antibody plus CHX. Upper panel shows that PARP cleavage,
a marker of apoptosis, had occurred in detached cells but not in the attached cells. Middle
panel shows that only the attached cells express ectopic YFP-CrmA or YFP-CrmA + NLS. An
anti-actin antibody was used as a control for equal protein loading (bottom panel).
the ability of CrmA to protect HeLa cells from Fas-induced
apoptosis.
DISCUSSION
It has recently become apparent that several members of the
serpin family localize, to a different extent, to the cell nucleus
[22,30–32]. Although it is predominantly localized in the
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cytoplasm, the viral anti-apoptotic serpin CrmA has been
proposed to enter the nucleus by diffusion through the nuclear
pores [22]. Our results, comparing the localization of Flag- and
YFP-tagged forms of CrmA, indicate that, in addition to passive
diffusion, active transport mechanisms can regulate the nucleo-
cytoplasmic localization of CrmA. The role of passive diffusion
is evident from the different subcellular distribution of Flag-
and YFP-tagged CrmA. As expected, the smaller Flag-CrmA
was more frequently detected in the nucleus. The involvement
of active nuclear import was first suggested by our observation
that YFP-CrmA partially accumulates in the nucleus of human
cells of different origin. YFP-CrmA is a 65 kDa protein whose
size would prevent passive diffusion through the nuclear pores,
thus requiring an active import process to enter the nucleus. Our
findings contrast with the reported inability of GFP-CrmA to
enter the nucleus of COS-1 cells [22], raising the possibility
that cell-type-specific factors may affect active nuclear import of
CrmA.
CrmA does not contain a classical NLS, such as the short stretch
of basic amino-acids (Lys74-Lys-Arg-Lys) that mediates nuclear
import of the cellular serpin PI-10 [30]. However, other cellular
members of the serpin family, such as PI-9, have been shown to
enter the nucleus using a non-conventional mechanism of active
import that does not rely on the presence of such sequences [22].
We show here that, like PI-9, CrmA is able to undergo CRM1-
mediated nuclear shuttling and it is possible that both serpins also
share similar import mechanisms. Blocking CRM1-dependent
nuclear export with LMB induced only a partial relocation of
CrmA to the nucleus, comparable with the LMB effect we have
previously observed on another shuttling protein, BRCA1 [25],
but smaller than the effect on HIV Rev [25] or survivin [33]. Thus
in comparison with that of PI-9, nuclear import of CrmA seems to
be a slow process. Interestingly, a CrmA deletion mutant lacking
the N-terminal 100 residues rapidly accumulates into the nucleus
upon LMB treatment, suggesting that the CrmA N-terminal region
may negatively regulate its nuclear import.
We have identified a motif in CrmA (G242SYNLVDALVK-
LGLTEVF; one-letter amino acid symbols, with bold letters
highlighting residues of interest) that constitutes an autonomous,
transferable leucine-rich NES. The activity of this novel NES is
comparable with that of HIV Rev export signal when tested using
an in vivo nuclear export assay [24]. Furthermore, we show that the
PI-9 sequence (E276DYDMESVLRHLGIVDAF), homologous
with CrmA NES, is also a functional, although weaker, NES. No
other export signals have been identified in this cellular serpin,
and the role of the NES reported here in the context of full-length
PI-9 remains to be established. Nevertheless, by comparison with
CrmA NES, we would predict that mutation of hydrophobic
residues conforming to the NES consensus sequence, such as
Leu287 and Ile289, would decrease PI-9 nuclear export.
Despite its strong activity in the nuclear export assay, the NES
appears to play only a partial role in CrmA nuclear export in
HeLa cells, a process that seems to be largely mediated by
additional sequences in the amino acid segment 200–303, flanking
the NES. This region does not contain other active leucine-rich
export signals but might represent a binding site for another
NES-containing protein, which may bridge the interaction with
CRM1. It is possible that the contribution of the NES to CrmA
export changes under different conditions. One must consider,
in this regard, that a prominent characteristic of serpins is their
conformational instability [34]. This property allows serpins
to adopt different conformations and may conceivably lead to
exposure or masking of different motifs, including the NES, under
different conditions. In this regard, we noted that mutational
inactivation of the NES had a dramatic effect in the context
of CrmA-(100–341). This observation suggests that deletion of
the N-terminal end leads not only to increased nuclear import
of CrmA, but also to exposure of the NES. More puzzling
is the observation that NES-inactivating mutations appear to
reduce nuclear import of CrmA in MCF-7 cells. The mechanism
underlying this effect remains to be established, but the different
consequences of the NES mutation in HeLa and MCF-7 cells
constitute a clear example that the cellular context may influence
the dynamics of CrmA nucleocytoplasmic transport.
The nuclear shuttling ability of CrmA raises the possibility
that it may carry out its anti-apoptotic function in the cytoplasm
and the nucleus. Testing this possibility was hampered by the
fact that the NES is not the only motif mediating CrmA export.
It was therefore not possible to completely abrogate this process
without deleting a large amino acid segment. This gross deletion
would presumably alter CrmA structure and function, preventing
a meaningful comparison with wild-type CrmA. As an alternative
approach to gain some insight into the functionality of CrmA in
the nucleus, we generated a chimaeric protein, fusing the NLS of
SV40 large T antigen to the C-terminal end of CrmA. Although
CrmA + NLS still has the potential to undergo nuclear export,
the strong NLS results in its rapid re-import into the nucleus.
Thus whereas YFP-CrmA is predominantly cytoplasmic, YFP-
CrmA + NLS accumulates strongly into the nucleus. Consistent
with the view that CrmA may have an anti-apoptotic activity in
the nucleus, we found that the ability of YFP-CrmA + NLS to
prevent Fas-induced apoptosis is fully preserved.
In summary, our results reveal that the subcellular localization
of CrmA is regulated in a more complex way than previously
suspected. Its ability to shuttle between nucleus and cytoplasm
may enable CrmA to efficiently target the pro-apoptotic proteins
caspase 1, caspase 8 and granzyme B for inactivation in either
cellular compartment. The two novel leucine-rich NESs reported
here are, to our knowledge, the first NESs to be identified in the
serpin family.
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